BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 11206100)

  • 1. Clinical benefits of a metabolic approach in the management of coronary patients.
    Marzilli M
    Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V25-30. PubMed ID: 11206100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
    Belardinelli R
    Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic therapy for patients with diabetes mellitus and coronary artery disease.
    Rosano GM; Vitale C; Fragasso G
    Am J Cardiol; 2006 Sep; 98(5A):14J-18J. PubMed ID: 16931201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy.
    Marazzi G; Gebara O; Vitale C; Caminiti G; Wajngarten M; Volterrani M; Ramires JA; Rosano G; Fini M
    Adv Ther; 2009 Apr; 26(4):455-61. PubMed ID: 19396409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy in angina: a review of combined haemodynamic treatment and the role for combined haemodynamic and cardiac metabolic agents.
    Jackson G
    Int J Clin Pract; 2001 May; 55(4):256-61. PubMed ID: 11406911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefits of a metabolic approach with trimetazidine in revascularized patients with angina.
    Danchin N
    Am J Cardiol; 2006 Sep; 98(5A):8J-13J. PubMed ID: 16931200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefits of a metabolic approach in the cardiac rehabilitation of patients with coronary artery disease.
    Belardinelli R; Lacalaprice F; Faccenda E; Volpe L
    Am J Cardiol; 2006 Sep; 98(5A):25J-33J. PubMed ID: 16931203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic value of trimetazidine in patients with coronary heart disease and left ventricular dysfunction].
    Multicentral Collaborative Group on Trimetazidine (Phase IV)
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Sep; 33(9):793-5. PubMed ID: 16266453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease: a placebo-controlled study.
    Pornin M; Harpey C; Allal J; Sellier P; Ourbak P
    Clin Trials Metaanal; 1994 Apr; 29(1):49-56. PubMed ID: 10150185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of trimetazidine added to maximal anti-ischemic therapy in patients with advanced coronary artery disease.
    Grabczewska Z; Białoszyński T; Szymański P; Sukiennik A; Swiatkiewicz I; Koziński M; Kochman W; Grześk G; Kubica J
    Cardiol J; 2008; 15(4):344-50. PubMed ID: 18698543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical benefits of trimetazidine in patients with recurrent angina.
    Szwed H
    Coron Artery Dis; 2004 May; 15 Suppl 1():S17-21. PubMed ID: 15179124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effects of trimetazidine on left ventricular function and physical exercise tolerance in patients with ischemic cardiomyopathy].
    Sisakian AS; Torgomian AL; Barkhudarian AL
    Klin Med (Mosk); 2006; 84(10):55-8. PubMed ID: 17201276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions.
    McClellan KJ; Plosker GL
    Drugs; 1999 Jul; 58(1):143-57. PubMed ID: 10439934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-ischaemic efficacy and tolerability of trimetazidine administered to patients with angina pectoris: results of three studies.
    Szwed H; Hradec J; Préda I
    Coron Artery Dis; 2001 Feb; 12 Suppl 1():S25-8. PubMed ID: 11286304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ischemic heart disease and left ventricular dysfunction: the role of trimetazidine].
    Belardinelli R
    Ital Heart J; 2004 Mar; 5 Suppl 2():23S-28S. PubMed ID: 15074774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of trimetazidine in management of ischemic cardiomyopathy.
    Bertomeu-Gonzalez V; Bouzas-Mosquera A; Kaski JC
    Am J Cardiol; 2006 Sep; 98(5A):19J-24J. PubMed ID: 16931202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.
    Vitale C; Wajngaten M; Sposato B; Gebara O; Rossini P; Fini M; Volterrani M; Rosano GM
    Eur Heart J; 2004 Oct; 25(20):1814-21. PubMed ID: 15474696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease.
    Rosano GM; Marazzi G; Patrizi R; Cerquetani E; Vitale C; Volterrani M; Fini M; Mercuro G
    Am J Cardiol; 2005 Feb; 95(3):327-31. PubMed ID: 15670539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimetazidine in Practice: Review of the Clinical and Experimental Evidence.
    Dézsi CA
    Am J Ther; 2016; 23(3):e871-9. PubMed ID: 25756467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.
    Belardinelli R; Lacalaprice F; Faccenda E; Volpe L
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):533-40. PubMed ID: 18797405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.